e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 28, 2010
QUESTCOR
PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
California
|
|
001-14758
|
|
33-0476164 |
|
|
|
|
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.) |
|
|
|
3260 Whipple Road, Union City, California
|
|
94587 |
(Address of Principal Executive Offices)
|
|
(Zip Code) |
Registrants telephone number, including area code: (510) 400-0700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b)) |
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 28, 2010, Questcor Pharmaceuticals, Inc., a California corporation (the Company),
held its annual meeting of shareholders. The Company solicited proxies for the meeting pursuant to
Regulation 14A under the Securities Exchange Act of 1934, as amended. As of the April 1, 2010
record date for the annual meeting, there were 62,040,454 shares of the Companys common stock
outstanding.
The Companys nominees for election to its board of directors as listed in the Companys proxy
statement were each elected to a one-year term, with the results of the voting as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Broker |
|
|
|
|
|
|
Votes |
|
Non- |
Nominee |
|
Votes For |
|
Withheld |
|
Votes |
Don M. Bailey |
|
|
41,822,326 |
|
|
|
585,457 |
|
|
|
8,596,592 |
|
Neal C. Bradsher |
|
|
41,589,281 |
|
|
|
818,502 |
|
|
|
8,596,592 |
|
Stephen C. Farrell |
|
|
42,070,629 |
|
|
|
337,154 |
|
|
|
8,596,592 |
|
Louis Silverman |
|
|
42,061,050 |
|
|
|
346,733 |
|
|
|
8,596,592 |
|
Virgil D. Thompson |
|
|
41,467,283 |
|
|
|
940,500 |
|
|
|
8,596,592 |
|
The Company also requested shareholder ratification of the selection of Odenberg, Ullakko,
Muranishi & Co. LLP (OUM) as the Companys independent registered public accounting firm for the
fiscal year ending December 31, 2010. As indicated below, the proposal to ratify the appointment
of OUM was approved:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Votes |
|
Votes |
|
|
Description |
|
For |
|
Against |
|
Abstain |
Ratification of Appointment of OUM |
|
|
49,913,185 |
|
|
|
1,062,352 |
|
|
|
28,838 |
|
As indicated in the above table, the proposal to ratify the appointment of OUM was approved.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
Date: June 4, 2010 |
QUESTCOR PHARMACEUTICALS, INC.
|
|
|
By: |
/s/ Gary M. Sawka
|
|
|
|
Gary M. Sawka |
|
|
|
Senior Vice President, Finance and Chief
Financial Officer |
|
|